Atossa Therapeutics, Inc.
ATOS
$2.40
-$0.12-4.57%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.80M | 5.09M | 5.28M | 3.88M | 3.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.69M | 9.87M | 11.44M | 9.25M | 9.04M |
| Operating Income | -8.69M | -9.87M | -11.44M | -9.25M | -9.04M |
| Income Before Tax | -8.49M | -9.59M | -10.94M | -8.69M | -8.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.49M | -9.59M | -10.94M | -8.69M | -8.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.49M | -9.59M | -10.94M | -8.69M | -8.42M |
| EBIT | -8.69M | -9.87M | -11.44M | -9.25M | -9.04M |
| EBITDA | -8.69M | -9.87M | -11.43M | -9.25M | -9.04M |
| EPS Basic | -0.95 | -1.11 | -1.27 | -1.01 | -0.98 |
| Normalized Basic EPS | -0.60 | -0.70 | -0.79 | -0.63 | -0.61 |
| EPS Diluted | -0.95 | -1.11 | -1.27 | -1.01 | -0.98 |
| Normalized Diluted EPS | -0.60 | -0.70 | -0.79 | -0.63 | -0.61 |
| Average Basic Shares Outstanding | 8.91M | 8.62M | 8.61M | 8.61M | 8.62M |
| Average Diluted Shares Outstanding | 8.91M | 8.62M | 8.61M | 8.61M | 8.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |